🔊CEOInterviews

James Clemmer on prostate cancer treatment

From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer · · IEEE EMBS

“We embarked on a study a few years ago called Preserve to show that the product can be used safely and effectively to treat men with intermediate risk prostate cancer. So we wanted to give the population between that another option to be treated using our nano knife, which our study proved could treat the organ, control the cancer, and reduce the chances of men having incontinence or impotence post treatment almost to zero.”

James Clemmer
Chief Executive Officer, President & Director, ANGIODYNAMICS INC
prostate cancer treatmentclinical outcomesfocal therapy

On , James Clemmer, Chief Executive Officer, President & Director at ANGIODYNAMICS INC, spoke about prostate cancer treatment during IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer on IEEE EMBS.

IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer
Watch on YouTube at 9:10
IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer
IEEE EMBS
Watch on YouTube at 9:10
In this episode of Industry Corner Live, Jim Clemmer, CEO of AngioDynamics, talks with IEEE Pulse Editor-in-Chief Chad Andresen about how the company transformed into a science-driven MedTech innovator focused on cancer and cardiovascular disease. Clemmer discusses the importance of physician collaboration, clinical evidence, and early reimbursement strategy in bringing breakthrough medical technologies to market. This conversation explores how leading MedTech companies are navigating market access, scaling innovation, and building sustainable growth in an increasingly data-driven healthcare landscape. Highlights: • How AngioDynamics repositioned itself as a science-first MedTech company. • The shift away from low-growth, commoditized products to high-impact innovation. • Why clinical evidence and physician trust are critical for adoption. • The role of reimbursement strategy in scaling new medical technologies. • Insights into key platforms like Auryon, AlphaVac, and NanoKnife. • How agility and data-driven decisions fuel long-term growth. • Lessons on leading transformation in a competitive healthcare market. Transcript: https://www.embs.org/pulse/articles/i...
James Clemmer

About James Clemmer

Chief Executive Officer, President & Director · ANGIODYNAMICS INC

In a December 2025 interview with IEEE Pulse, AngioDynamics CEO Jim Clemmer discussed the company's transformation into a science-driven MedTech innovator focused on cancer and cardiovascular disease. Clemmer described the company's strategy of active portfolio management, stating, "It took active portfolio management, which is easy to say, hard to do. So, we divested some assets that actually provided revenue and profit for the company." He also highlighted the company's market performance, saying, "Now five years post launch, we're already taking a number three position in market share, past three of those really big powerful companies." Clemmer emphasized the importance of physician collaboration, clinical evidence, and early reimbursement strategy in bringing breakthrough medical technologies to market. He noted that AngioDynamics obtained a CPT-1 code before receiving 510K clearance, which he described as unusual in his experience. Clemmer also discussed the challenges of market access, stating, "Market access can be really, really challenging and teams need to really think that through and have a really good strategy." He shared his background starting as a sales representative in 1989 and described how the company engaged with physicians to build trust and support for its products.

Profile compiled from James Clemmer's verified public interviews and appearances. See all quotes & transcripts →

More from James Clemmer ANGIODYNAMICS INC (ANGO) Full Transcript Explore All Executives